To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

NCT05253053 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

84

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor
Cholangiocarcinoma
Biliary Tract Cancer
HER2-negative Breast Cancer
Triple Negative Breast Cancer
Small-cell Lung Cancer
Bladder Cancer
Prostate Cancer
Thyroid Cancer
Gastric Cancer
Gallbladder Cancer

Interventions

DRUG: TT-00420
DRUG: Combination Product: Atezolizumab
DRUG: Combination Product: Nab-Paclitaxel

Sponsor

TransThera Sciences (Nanjing), Inc.